RxDoctor Payments Data

Ann Grady, MD

Cardiovascular Disease · Fall River, MANPI 1689676876

Payments from drug & device makers

$3,801in general payments, 2019–2025

Across 247 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$374
  • Astellas Pharma US Inc$288
  • Novo Nordisk$286
  • AstraZeneca$276
  • Amgen$275
  • Boehringer Ingelheim$260
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,48992%
  • Education$3128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,801 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$236,872
Medicare patients
306
Services billed
6,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide177$195,961
EliquisApixaban167$175,923
OzempicSemaglutide101$114,993
JardianceEmpagliflozin55$63,414
XareltoRivaroxaban36$47,159
Repatha SureclickEvolocumab49$38,163
LinzessLinaclotide50$37,780
Janumet XrSitagliptin Phos/Metformin Hcl25$29,424
Diclofenac Potassium17$26,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,545
MyrbetriqMirabegron17$19,755
Rosuvastatin Calcium599$16,255
Valsartan297$9,350
VascepaIcosapent Ethyl22$9,151
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide211$7,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$146$195,961177 claims
PfizerEliquis$374$175,923167 claims
Novo NordiskOzempic$286$114,993101 claims
Boehringer IngelheimJardiance, Stiolto Respimat$260$68,83666 claims
Johnson & JohnsonXarelto$207$47,15936 claims
AbbVieLinzess, Synthroid$186$41,723121 claims
MerckJanumet Xr$138$29,42425 claims
GSKTrelegy Ellipta, Breo Ellipta$217$25,72342 claims
Astellas Pharma US IncMyrbetriq$288$19,75517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →